Large-scale screening for somatic mutations in lung cancer
In squamous-cell carcinoma and small-cell lung carcinomas, several novel driver mutations are being investigated as potentially actionable targets: amplification of FGFR1, PIK3CA,9 and the sequence of the entire 3·2 kb coding region of DDR2.5,10DDR2 mutations can be detected at a frequency of 3% in...
Gespeichert in:
| Veröffentlicht in: | The Lancet (British edition) 2016-04, Vol.387 (10026), p.1354-1356 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1356 |
|---|---|
| container_issue | 10026 |
| container_start_page | 1354 |
| container_title | The Lancet (British edition) |
| container_volume | 387 |
| creator | Rosell, Rafael Karachaliou, Niki |
| description | In squamous-cell carcinoma and small-cell lung carcinomas, several novel driver mutations are being investigated as potentially actionable targets: amplification of FGFR1, PIK3CA,9 and the sequence of the entire 3·2 kb coding region of DDR2.5,10DDR2 mutations can be detected at a frequency of 3% in both adenocarcinoma and squamous-cell carcinoma.11 On the basis of this knowledge, new initiatives for treatment of lung squamous-cell carcinoma are in progress, such as the Lung Cancer Master Protocol (Lung-MAP), a unique public-private partnership in the USA, including the US Food and Drug Administration.12 The Network Genomic Medicine (NGM) in Cologne, Germany, was the first group to describe distribution of genotypes and survival with targeted therapy compared with chemotherapy in distinct genotypes.10 Since then, the NGM has made great progress, implementing genotyping by next-generation sequencing as well as other initiatives in implementing genomic-driven treatment trials, such as for ROS1 (EUCROSS; NCT02183870).13 The Lung Cancer Mutation Consortium (LCMC) determined the frequency of oncogenic drivers, the proportion of patients treated with genotype-directed therapy, and survival in 1007 patients in the USA. |
| doi_str_mv | 10.1016/S0140-6736(15)01125-3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1785215239</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0140673615011253</els_id><sourcerecordid>1785215239</sourcerecordid><originalsourceid>FETCH-LOGICAL-c566t-60198f7f76cb320118538c943431894f318883fb3383293605d8a36a38501cea3</originalsourceid><addsrcrecordid>eNqFkU1LJDEQhsOi6Dj6E3Zp8KKH1lRX56M9KCK7qzDgQQVvIZOplmh_aNK94L83M-MqePGSOuSptypPGPsJ_Ag4yOMbDiXPpUJ5AOKQAxQixx9sAqUqc1Gq-w02-UC22U6Mj5zzUnKxxbYLqZSqQE_YycyGB8qjsw1l0QWizncPWd2HLPatHbzL2nFIte9i5rusGdOts52jsMs2a9tE2nuvU3b35_ftxWU-u_57dXE-y52Qcsglh0rXqlbSzbFIi2qB2lUllgi6Kut0ao31HFFjUWFacKEtSotacHBkccoO1rnPoX8ZKQ6m9dFR09iO-jEaUFoUIAqsErr_BX3sx9Cl7ZYUL0DyNH3KxJpyoY8xUG2eg29teDXAzVKuWck1S3MGhFnJNZj6fr2nj_OWFh9d_20m4GwNUNLxz1Mw0XlKrhY-kBvMovffjjj9kuAa3_n0O0_0SvHzNSYWhq9DlhkgVgmIb8N-miI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1780216085</pqid></control><display><type>article</type><title>Large-scale screening for somatic mutations in lung cancer</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><source>ProQuest Central UK/Ireland</source><creator>Rosell, Rafael ; Karachaliou, Niki</creator><creatorcontrib>Rosell, Rafael ; Karachaliou, Niki</creatorcontrib><description>In squamous-cell carcinoma and small-cell lung carcinomas, several novel driver mutations are being investigated as potentially actionable targets: amplification of FGFR1, PIK3CA,9 and the sequence of the entire 3·2 kb coding region of DDR2.5,10DDR2 mutations can be detected at a frequency of 3% in both adenocarcinoma and squamous-cell carcinoma.11 On the basis of this knowledge, new initiatives for treatment of lung squamous-cell carcinoma are in progress, such as the Lung Cancer Master Protocol (Lung-MAP), a unique public-private partnership in the USA, including the US Food and Drug Administration.12 The Network Genomic Medicine (NGM) in Cologne, Germany, was the first group to describe distribution of genotypes and survival with targeted therapy compared with chemotherapy in distinct genotypes.10 Since then, the NGM has made great progress, implementing genotyping by next-generation sequencing as well as other initiatives in implementing genomic-driven treatment trials, such as for ROS1 (EUCROSS; NCT02183870).13 The Lung Cancer Mutation Consortium (LCMC) determined the frequency of oncogenic drivers, the proportion of patients treated with genotype-directed therapy, and survival in 1007 patients in the USA.</description><identifier>ISSN: 0140-6736</identifier><identifier>EISSN: 1474-547X</identifier><identifier>DOI: 10.1016/S0140-6736(15)01125-3</identifier><identifier>PMID: 26777918</identifier><identifier>CODEN: LANCAO</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Cancer therapies ; Carcinoma, Non-Small-Cell Lung - genetics ; Female ; Gene Expression Profiling ; Genotypes ; Humans ; Internal Medicine ; Kinases ; Lung cancer ; Lung Neoplasms - genetics ; Male ; Medical screening ; Mutation ; Public private partnerships</subject><ispartof>The Lancet (British edition), 2016-04, Vol.387 (10026), p.1354-1356</ispartof><rights>Elsevier Ltd</rights><rights>2016 Elsevier Ltd</rights><rights>Copyright Elsevier Limited Apr 2, 2016</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c566t-60198f7f76cb320118538c943431894f318883fb3383293605d8a36a38501cea3</citedby><cites>FETCH-LOGICAL-c566t-60198f7f76cb320118538c943431894f318883fb3383293605d8a36a38501cea3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/1780216085?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995,64385,64387,64389,72469</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26777918$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rosell, Rafael</creatorcontrib><creatorcontrib>Karachaliou, Niki</creatorcontrib><title>Large-scale screening for somatic mutations in lung cancer</title><title>The Lancet (British edition)</title><addtitle>Lancet</addtitle><description>In squamous-cell carcinoma and small-cell lung carcinomas, several novel driver mutations are being investigated as potentially actionable targets: amplification of FGFR1, PIK3CA,9 and the sequence of the entire 3·2 kb coding region of DDR2.5,10DDR2 mutations can be detected at a frequency of 3% in both adenocarcinoma and squamous-cell carcinoma.11 On the basis of this knowledge, new initiatives for treatment of lung squamous-cell carcinoma are in progress, such as the Lung Cancer Master Protocol (Lung-MAP), a unique public-private partnership in the USA, including the US Food and Drug Administration.12 The Network Genomic Medicine (NGM) in Cologne, Germany, was the first group to describe distribution of genotypes and survival with targeted therapy compared with chemotherapy in distinct genotypes.10 Since then, the NGM has made great progress, implementing genotyping by next-generation sequencing as well as other initiatives in implementing genomic-driven treatment trials, such as for ROS1 (EUCROSS; NCT02183870).13 The Lung Cancer Mutation Consortium (LCMC) determined the frequency of oncogenic drivers, the proportion of patients treated with genotype-directed therapy, and survival in 1007 patients in the USA.</description><subject>Cancer therapies</subject><subject>Carcinoma, Non-Small-Cell Lung - genetics</subject><subject>Female</subject><subject>Gene Expression Profiling</subject><subject>Genotypes</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Kinases</subject><subject>Lung cancer</subject><subject>Lung Neoplasms - genetics</subject><subject>Male</subject><subject>Medical screening</subject><subject>Mutation</subject><subject>Public private partnerships</subject><issn>0140-6736</issn><issn>1474-547X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkU1LJDEQhsOi6Dj6E3Zp8KKH1lRX56M9KCK7qzDgQQVvIZOplmh_aNK94L83M-MqePGSOuSptypPGPsJ_Ag4yOMbDiXPpUJ5AOKQAxQixx9sAqUqc1Gq-w02-UC22U6Mj5zzUnKxxbYLqZSqQE_YycyGB8qjsw1l0QWizncPWd2HLPatHbzL2nFIte9i5rusGdOts52jsMs2a9tE2nuvU3b35_ftxWU-u_57dXE-y52Qcsglh0rXqlbSzbFIi2qB2lUllgi6Kut0ao31HFFjUWFacKEtSotacHBkccoO1rnPoX8ZKQ6m9dFR09iO-jEaUFoUIAqsErr_BX3sx9Cl7ZYUL0DyNH3KxJpyoY8xUG2eg29teDXAzVKuWck1S3MGhFnJNZj6fr2nj_OWFh9d_20m4GwNUNLxz1Mw0XlKrhY-kBvMovffjjj9kuAa3_n0O0_0SvHzNSYWhq9DlhkgVgmIb8N-miI</recordid><startdate>20160402</startdate><enddate>20160402</enddate><creator>Rosell, Rafael</creator><creator>Karachaliou, Niki</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TT</scope><scope>0TZ</scope><scope>0U~</scope><scope>3V.</scope><scope>7QL</scope><scope>7QP</scope><scope>7RV</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88C</scope><scope>88E</scope><scope>88G</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8C1</scope><scope>8C2</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>ASE</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FPQ</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K6X</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>KB~</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>S0X</scope><scope>7X8</scope></search><sort><creationdate>20160402</creationdate><title>Large-scale screening for somatic mutations in lung cancer</title><author>Rosell, Rafael ; Karachaliou, Niki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c566t-60198f7f76cb320118538c943431894f318883fb3383293605d8a36a38501cea3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Cancer therapies</topic><topic>Carcinoma, Non-Small-Cell Lung - genetics</topic><topic>Female</topic><topic>Gene Expression Profiling</topic><topic>Genotypes</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Kinases</topic><topic>Lung cancer</topic><topic>Lung Neoplasms - genetics</topic><topic>Male</topic><topic>Medical screening</topic><topic>Mutation</topic><topic>Public private partnerships</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rosell, Rafael</creatorcontrib><creatorcontrib>Karachaliou, Niki</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>News PRO</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Global News & ABI/Inform Professional</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Lancet Titles</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>British Nursing Index</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>British Nursing Index</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Newsstand Professional</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><jtitle>The Lancet (British edition)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rosell, Rafael</au><au>Karachaliou, Niki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Large-scale screening for somatic mutations in lung cancer</atitle><jtitle>The Lancet (British edition)</jtitle><addtitle>Lancet</addtitle><date>2016-04-02</date><risdate>2016</risdate><volume>387</volume><issue>10026</issue><spage>1354</spage><epage>1356</epage><pages>1354-1356</pages><issn>0140-6736</issn><eissn>1474-547X</eissn><coden>LANCAO</coden><abstract>In squamous-cell carcinoma and small-cell lung carcinomas, several novel driver mutations are being investigated as potentially actionable targets: amplification of FGFR1, PIK3CA,9 and the sequence of the entire 3·2 kb coding region of DDR2.5,10DDR2 mutations can be detected at a frequency of 3% in both adenocarcinoma and squamous-cell carcinoma.11 On the basis of this knowledge, new initiatives for treatment of lung squamous-cell carcinoma are in progress, such as the Lung Cancer Master Protocol (Lung-MAP), a unique public-private partnership in the USA, including the US Food and Drug Administration.12 The Network Genomic Medicine (NGM) in Cologne, Germany, was the first group to describe distribution of genotypes and survival with targeted therapy compared with chemotherapy in distinct genotypes.10 Since then, the NGM has made great progress, implementing genotyping by next-generation sequencing as well as other initiatives in implementing genomic-driven treatment trials, such as for ROS1 (EUCROSS; NCT02183870).13 The Lung Cancer Mutation Consortium (LCMC) determined the frequency of oncogenic drivers, the proportion of patients treated with genotype-directed therapy, and survival in 1007 patients in the USA.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>26777918</pmid><doi>10.1016/S0140-6736(15)01125-3</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0140-6736 |
| ispartof | The Lancet (British edition), 2016-04, Vol.387 (10026), p.1354-1356 |
| issn | 0140-6736 1474-547X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1785215239 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete; ProQuest Central UK/Ireland |
| subjects | Cancer therapies Carcinoma, Non-Small-Cell Lung - genetics Female Gene Expression Profiling Genotypes Humans Internal Medicine Kinases Lung cancer Lung Neoplasms - genetics Male Medical screening Mutation Public private partnerships |
| title | Large-scale screening for somatic mutations in lung cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T07%3A15%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Large-scale%20screening%20for%20somatic%20mutations%20in%20lung%20cancer&rft.jtitle=The%20Lancet%20(British%20edition)&rft.au=Rosell,%20Rafael&rft.date=2016-04-02&rft.volume=387&rft.issue=10026&rft.spage=1354&rft.epage=1356&rft.pages=1354-1356&rft.issn=0140-6736&rft.eissn=1474-547X&rft.coden=LANCAO&rft_id=info:doi/10.1016/S0140-6736(15)01125-3&rft_dat=%3Cproquest_cross%3E1785215239%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1780216085&rft_id=info:pmid/26777918&rft_els_id=S0140673615011253&rfr_iscdi=true |